StockNews.com upgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a hold rating to a buy rating in a research note ...

StockNews.com downgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning. Separately, Scotiabank assumed ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as ...

GSK also manufactures Advair, Anoro Ellipta and Arnuity Ellipta for asthma. It also manufactures Augmentin, an antibiotic used to treat various bacterial infections. GSK’s exit and change of model ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. Innoviva’s other innovative healthcare assets include infectious disease and ...

Some GSK also manufactures Advair, Anoro Ellipta and Arnuity Ellipta for asthma. Their exit and change of model have put pressure on patients who now spend more than 100 per cent more than the usual ...

A royalty stream from GlaxoSmithKline's Breo Ellipta and Anoro Ellipta provides a robust revenue backbone and financial insulation not often seen in the biopharma space. This constant revenue ...

Sales of Trelegy Ellipta and Flixotide/Flovent surged 17% and 47%, respectively. Sales of Advair/Seretide and Anoro Ellipta fell 2% each. Revlar/Breo Ellipta sales declined 5%. The decline in ...

Check this table to make sure you can use your COPD inhalers together Medically reviewed by Sanja Jelic, MD Most people with ...